---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-24-000044"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:37:01.365747+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics appoints Alan V. Mateo to Board of Directors

## Summary
- Alan V. Mateo appointed as Class II director effective June 18, 2024, term until 2027 annual meeting.
- Mateo previously Executive VP Global Sales at Veeva Systems, executive roles at Medidata Solutions and PeopleSoft.
- Receives $55k annual cash retainer, $400k initial RSU grant (July 31, 2024), and $215k annual RSU grant.
- Compensation includes standard indemnification agreement; eligible for additional committee service retainers.

## SEC filing metadata
- accession: 0001770787-24-000044
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000044/0001770787-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000044/txg-20240618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-24-000044
- JSON: https://secwatch.observer/filing/0001770787-24-000044.json
- Plain text: https://secwatch.observer/filing/0001770787-24-000044.txt

## Key facts
- Executive change
  Alan V. Mateo was appointed as Director at 10x Genomics, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Alan V. Mateo to the Board of Directors as a Class II director effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000044/0001770787-24-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.